LA JOLLA, Calif.--(BUSINESS WIRE)--CytoHub, Inc., a pioneering developer of intelligent technologies for cell therapy and regenerative medicine, today announced the strategic addition of three top industry experts to its team. David DiGiusto, Ph.D., joins as Technical, Scientific, and Strategic Advisor; Aitor Aguirre, Ph.D., as Scientific Advisor and Lead of Organoid Platform; and Frank Teoh as VP of Engineering, Global Head of BioEngineAI™ Platform..

加利福尼亚州拉霍亚市（商业新闻短讯）--细胞疗法和再生医学智能技术的先驱CytoHub，Inc.今天宣布，其团队将战略性地增加三名顶尖行业专家。David DiGiusto博士加入，担任技术，科学和战略顾问；Aitor Aguirre博士，科学顾问和类器官平台负责人；Frank Teoh担任工程副总裁、BioEngineAI™平台全球负责人。。

These appointments mark a significant enhancement of CytoHub’s leadership, aligning with the company’s commitment to advancing biomanufacturing innovations in cell therapy and regenerative medicine. David DiGiusto, Ph.D., brings over three decades of experience in translational medicine and GMP compliant iPSC derived cells as therapeutics agents and biologics manufacturing.

这些任命标志着CytoHub领导地位的显着提高，与该公司致力于推进细胞疗法和再生医学中的生物制造创新相一致。David DiGiusto博士在转化医学和符合GMP的iPSC衍生细胞作为治疗剂和生物制剂制造方面拥有三十多年的经验。

Aitor Aguirre, Ph.D., a distinguished researcher in tissue engineering and Associate Professor of Biomedical Engineering at MSU, will spearhead the company's new Organoid Platform, and Frank Teoh, with extensive experience in Machine Learning, Artificial Intelligence and Cloud services, will lead the BioEngineAI™ Platform..

组织工程杰出研究员、密歇根州立大学生物医学工程副教授Aitor Aguirre博士将领导公司新的类器官平台，在机器学习、人工智能和云服务方面拥有丰富经验的Frank Teoh将领导BioEngineAI™平台。。

'The combined expertise of David, Aitor, and Frank is pivotal as we propel our innovations and make advanced cell therapies and regenerative medicine more accessible and affordable for everyone,' said Rajib Biswas, Ph.D., Founder and CEO of CytoHub, adding further, “Their addition positions CytoHub at the forefront of scientific and technical innovation.”.

CytoHub创始人兼首席执行官拉吉布·比斯瓦斯（RajibBiswas）博士说：“大卫（David）、艾托尔（Aitor）和弗兰克（Frank）的综合专业知识至关重要，因为我们推动了我们的创新，使先进的细胞疗法和再生医学更容易为每个人所接受和负担得起。”他进一步补充道，“他们的加入使CytoHub处于科技创新的前沿。”。

David DiGiusto, Ph.D., expressed his enthusiasm: “Joining CytoHub offers a thrilling opportunity to harness cutting-edge technologies vital for advancing biomanufacturing processes. These innovations are crucial for the field of regenerative medicine, and CytoHub will be at the center of this movement.”.

David DiGiusto博士表达了他的热情：“加入CytoHub提供了一个激动人心的机会，可以利用对推进生物制造过程至关重要的尖端技术。这些创新对再生医学领域至关重要，CytoHub将成为这场运动的中心。”。

Aitor Aguirre, Ph.D., added, 'Novel organoid technologies are revolutionizing regenerative medicine, and I am eager to accelerate ethical drug development with state-of-the-art AI and human organoid technologies at CytoHub.”

Aitor Aguirre博士补充道：“新型类器官技术正在彻底改变再生医学，我渴望在CytoHub利用最先进的人工智能和人类类器官技术加速道德药物的开发。”

Frank Teoh also reflected on his new role and stated, 'Integrating AI and ML to scale biomanufacturing marks an exciting era. CytoHub is at the forefront of this industrialized biology, driving cell therapy and regenerative medicine innovations. It's thrilling to join a pioneering force in the field.'.

Frank Teoh还反思了他的新角色，并表示，“将AI和ML整合到规模化生物制造中标志着一个激动人心的时代。CytoHub是这种工业化生物学的前沿，推动细胞疗法和再生医学创新。加入这一领域的先锋力量是令人兴奋的。”。

About CytoHub, Inc.:

关于CytoHub，Inc.：

CytoHub, Inc. is a biotech company dedicated to transforming cell therapy and regenerative medicine development and biomanufacturing with its innovative technologies and platforms. With a commitment to excellence and a focus on pioneering solutions, CytoHub aims to bridge the gap between laboratory research and practical medical applications, ultimately improving patient outcomes worldwide..

CytoHub，Inc.是一家生物技术公司，致力于通过其创新技术和平台改造细胞疗法和再生医学开发以及生物制造。CytoHub致力于卓越，专注于开创性解决方案，旨在弥合实验室研究与实际医学应用之间的差距，最终改善全球患者的预后。。